Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Combined use of ruxolitinib and sirolimus: increased monitoring of triglycerides required

Bone Marrow Transplantation volume 54, pages 1372–1373 (2019)Cite this article

Subjects

Despite significant improvements in hematopoietic stem cell transplantation (HSCT) in the past decades, corticosteroid-refractory chronic graft-versus-host disease (cGvHD) represents a leading cause of non-relapse mortality and morbidity after allogeneic HSCT [1, 2]. Salvage therapy for corticosteroid-refractory cGvHD includes agents with an adequate safety profile and well-documented activity like calcineurin inhibitors, mTOR inhibitors, mycophenolate mofetil, and extracorporeal photopheresis [1, 2].

New treatment options enter clinical practice including the Janus-Associated Kinases (JAKs) inhibitors [3]. Ruxolitinib (Jakavi®, Novartis, Ireland) is an oral selective inhibitor of JAK1 and JAK2, licensed for myelofibrosis and polycythaemia. Prospective clinical trials are on-going in adults and children to evaluate its safety and efficacy in patients with acute and chronic corticosteroid-refractory GvHD (www.clinicaltrials.gov).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

References

  1. Hill L, Alousi A, Kebriaei P, Mehta R, Rezvani K, Shpall E. New and emerging therapies for acute and chronic graft versus host disease. Ther Adv Hematol. 2018;9:21–46.

    Article  CAS  Google Scholar 

  2. MacDonald KPA, Betts BC, Couriel D. Emerging therapeutics for the control of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2018;24:19–26.

    Article  Google Scholar 

  3. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015;29:2062–8.

    Article  CAS  Google Scholar 

  4. Watson AP, Brunstein CG, Holtan SG. Life-threatening hypertriglyceridemia in a patient on ruxolitinib and sirolimus for chronic graft-versus-host disease. Case Rep Transplant. 2018;2018:4539757.

    PubMed  PubMed Central  Google Scholar 

  5. Common Terminology Criteria for Adverse Events (CTCAE). https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology, Oncology and Hematopoietic Stem Cell Transplantation, Ghent University Hospital, C. Heymanslaan 10, Ghent, 9000, Belgium

    Tiene Bauters, Victoria Bordon, Geneviève Laureys & Catharina Dhooge

Authors
  1. Tiene Bauters
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Victoria Bordon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Geneviève Laureys
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Catharina Dhooge
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tiene Bauters.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bauters, T., Bordon, V., Laureys, G. et al. Combined use of ruxolitinib and sirolimus: increased monitoring of triglycerides required. Bone Marrow Transplant 54, 1372–1373 (2019). https://doi.org/10.1038/s41409-019-0488-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41409-019-0488-2

This article is cited by

Search

Advanced search

Quick links